The Caffeine Therapy in the Fetal to Neonatal Transition
NCT05454332 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2025-04-02
Summary
Introduction: The caffeine is used in the treatment for apnea of prematurity and it has several positive effects in the neurodevelopment of preterm babies. There are innumerable observational studies suggesting that initiating caffeine in the first hours of life may offer more benefits in the reduction of the necessity of intubation and in ventilation time. It is necessary to expand further research on the best time to start caffeine, which may improve the quality of care for premature infants.
Objective: To evaluate the benefits of caffeine administration in the first two hours of life compared to administration at 24 hours of life in premature patients on noninvasive mechanical ventilation with birth weights less than 1250 grams.
Methodology: Preterm newborn patients with birth weight \< 1250 grams born at Hospital de Clínicas de Porto Alegre who are not intubated in the delivery room will be included. Patients will be randomized into two groups. One arm of the study will receive caffeine at 2 hours of age and the other arm will receive caffeine at 24 hours of age (control). Patients in the control group will receive 0.9% SF at 2 hours of life in order to keep the study blinded. The following outcomes will be evaluated: need for intubation, time on invasive and non-invasive mechanical ventilation, BPD, necrotizing enterocolitis, need for ROP treatment, PDA with hemodynamic repercussions, peri-intraventricular hemorrhage, leukomalacia and death. The sample size calculation is 50 patients, 25 in each arm.
Expected Results: It is expected to find a 43% reduction in the need for intubation in preterm infants who receive caffeine in the first two hours of life compared to administration at 24 hours of life. It is also expected to find a reduction in mechanical ventilation time, in addition to a possible reduction in negative outcomes associated with prematurity.
Conditions
- Mechanical Ventilation Complication
- Caffeine
- Ventilator Lung; Newborn
Interventions
- DRUG
-
Early Caffeine administration
Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
- OTHER
-
Control Group
Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
Sponsors & Collaborators
-
Hospital de Clinicas de Porto Alegre
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Max Age
- 2 Hours
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-27
- Primary Completion
- 2025-12-31
- Completion
- 2026-08-30
Countries
- Brazil
Study Locations
More Related Trials
-
Caffeine Treatment in in the Delivery Room
NCT04044976 ·Status: COMPLETED ·Phase: NA
-
Caffeine Use in the Management of Preterm Infants
NCT06327152 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Caffeine for Preterm Infants With Apnea of Prematurity(AOP)
NCT03298347 ·Status: UNKNOWN ·Phase: NA
-
Early Caffeine in Preterm Neonates
NCT03086473 ·Status: UNKNOWN ·Phase: PHASE4
-
Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea
NCT01911182 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
High Versus Low Dose of Caffeine for Apnea of Prematurity
NCT02103777 ·Status: COMPLETED ·Phase: PHASE3
-
Caffeine for Apnea of Prematurity (CAP)
NCT00182312 ·Status: COMPLETED ·Phase: PHASE3
-
Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress
NCT06026163 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Prophylactic Versus Therapeutic Caffeine for Apnea of Prematurity
NCT02677584 ·Status: COMPLETED ·Phase: NA
-
Intermittent Hypoxia and Caffeine in Infants Born Preterm
NCT03321734 ·Status: COMPLETED ·Phase: PHASE2
-
Oxygen Saturation and Caffeine Post-Discharge
NCT02386046 ·Status: TERMINATED
-
The Effect of Stimulating Substances on Brain Activity of Preterm Infants
NCT01344317 ·Status: UNKNOWN
-
Caffeine Citrate Use and Electronic Activity of the Diaphragm (EDI) Changes
NCT05393817 ·Status: COMPLETED
-
Caffeine Citrate to Improve Neonatal Outcomes.
NCT06972849 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Target Weaning Oxygen to Determine Cafffeine Duration for AOP
NCT04868565 ·Status: COMPLETED ·Phase: PHASE4
-
The Role of Electroencephalography in Caffeine Discontinuation Timing in Premature Infants
NCT07324941 ·Status: RECRUITING
-
Apnea of Prematurity Results in Respiratory Distress and Cyanosis. Caffeine Citrate Can Treat It.
NCT06905496 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Early Versus Late Caffeine for ELBW Newborns
NCT02524249 ·Status: TERMINATED ·Phase: NA
-
Cpap at Delivery Room for Preterm Infants
NCT01024361 ·Status: UNKNOWN ·Phase: PHASE4
-
PK and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia
NCT05295784 ·Status: WITHDRAWN ·Phase: PHASE1
-
Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm
NCT01875159 ·Status: COMPLETED ·Phase: PHASE3
-
Baby-CINO: CaffeINe Treatment Optimisation in Premature Infants
NCT06416956 ·Status: RECRUITING
-
Management of Apnea in Late Preterm and Term Infants
NCT02408328 ·Status: WITHDRAWN ·Phase: PHASE2
-
Early NCPAP Before Surfactant Treatment in Very Preterm Infants With RDS
NCT01996670 ·Status: COMPLETED
-
Successful Extubation and Noninvasive Ventilation in Preterm ≤ 1500g Terms
NCT02396693 ·Status: COMPLETED ·Phase: NA